07:00 , Apr 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Artemin (ARTN); glial cell line-derived neurotrophic factor family receptor α 3 (GFRα3)

Neurology INDICATION: Pain Mouse studies suggest inhibiting GFRα3 or its ligand ARTN could help treat cold allodynia. In mouse models of inflammatory pain, nerve injury and chemotherapy-induced pain, GFRα3 knockout decreased cold allodynia compared with...
07:00 , Jul 13, 2015 |  BioCentury  |  Finance

Big news

The performance of big cap biotechs has lagged that of companies one tier down, but the second half includes a host of milestones that could put the bellwethers on a steeper upward trajectory. Buysiders largely...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

Neublastin artemin/enovin: Interim Phase I data

Interim data from 16 sciatic patients in a single-blind, placebo-controlled, Dutch Phase I trial showed that multiple doses of IV Neublastin were well tolerated with no treatment-related serious adverse events reported. Biogen Idec said that...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

Neublastin artemin/enovin: Phase I data

A single-blind, placebo-controlled, Australian Phase I trial in 44 sciatic patients showed that single doses of IV Neublastin were well tolerated with no treatment-related serious adverse events reported. Biogen Idec has exclusive, worldwide rights to...
07:00 , Aug 16, 2010 |  BC Week In Review  |  Company News

Biogen Idec, NsGene deal

The partners granted Biogen Idec exclusive, worldwide rights to develop and commercialize Neublastin artemin/enovin for all indications under an amended 2000 deal that granted Biogen Idec rights to Neublastin to treat multiple sclerosis (MS) and...
07:00 , Sep 7, 2009 |  BC Week In Review  |  Clinical News

Neublastin artemin/enovin: Phase I started

Biogen Idec began a single-blind, placebo-controlled, dose-escalation, Australian Phase I trial to evaluate single doses of IV Neublastin in 28 patients. The trial start triggers an undisclosed milestone payment to NsGene from Biogen Idec, which...
07:00 , Mar 31, 2008 |  BC Week In Review  |  Clinical News

Biogen Idec, NsGene preclinical data

Data from rats with dorsal root crush showed that Neublastin artemin promoted the regeneration of damaged sensory nerve cells and restored sensory and motor function for more than 6 months. Animals received six subcutaneous injections...
07:00 , Jul 12, 2004 |  BioCentury  |  Product Development

Neurotrophic factor frustration

Last month, Amgen Inc. 's recombinant glial-derived neurotrophic factor became the latest in almost a decade's worth of clinical failures for the class. But researchers still believe in the therapeutic potential of neurotrophic factors based...
07:00 , Oct 13, 2003 |  BC Week In Review  |  Clinical News

Biogen preclinical data

Researchers published in Nature Medicine that artemin produced dose- and time-related reversal of nerve injury-induced pain behavior in rodents. Additionally, the compound led to partial to complete normalization of multiple morphological and neurochemical features of...